RESTORE+

RESTORE+ is a GalNAc-conjugated RNA editing platform developed by AIRNA Bio that utilizes endogenous Adenosine Deaminase Acting on RNA (ADAR) to achieve precise, reversible, and programmable A-to-I (adenosine-to-inosine) edits at the RNA level. The platform is designed to introduce genetically validated gain-of-function or protective variants into target transcripts to treat diseases with high unmet needs, such as atherosclerotic cardiovascular disease (ASCVD). In preclinical studies, RESTORE+ oligonucleotides have been used to introduce a single A-to-G edit in the 3'UTR of the Low Density Lipoprotein Receptor (LDLR) to increase its expression, as well as to introduce protective variants in the Apolipoprotein B (APOB) transcript. This approach aims to provide a safer and more effective alternative to traditional loss-of-function therapies by directly enhancing protein function or expression.

Brand names

RESTORE+